The release of CannaStrips has been five years in the making. Since then, the company has overcome regulatory hurdles, slides in share price and a host of equipment failures to bring their long-awaited product to market.
In that time, the company has worked to improve the product’s efficacy. CannaStrips, like breath strips, allow for the–much needed–accurate dosing which has long evaded cannabis-infused edibles.
The Journal of the American Medical Association (JAMA) published a research letter in 2015 which found only 17 percent of cannabis edibles observed accurately informed consumers about their THC content.
CannaStrips are formulated using a pharma-grade approach to guarantee the same consistency expected from a tablet of ibuprofen.
“Our goal has always been to produce a dependable high quality product at an affordable price point. We want to remove any competition from the purchase decision, so that every customer can leave the dispensary with a package of CannaStripsTM without significant impact to their purse or wallet.”
-Brad Eckenweiler, LDS’ CEO
CannaStrips fill a void for many medical cannabis patients. For example, consider those who suffer from Chronic Obstructive Pulmonary Disease (COPD).
The benefits of medical cannabis for COPD
- It promotes better sleep, which is critical for healing and cellular repair
- Cannabis supports the immune system
- Marijuana is an expectorant, helping the lungs to bring up/expel excess phlegm from the lungs
- Medical cannabis reduces pain
COPD causes inflammation and constriction of the airways. Because of the effect COPD has on the lungs, the anti-inflammatory cannabinoids which can reduce inflammation cannot be absorbed through inhalation without pain.
As noted above, however, traditional edibles are often mislabeled and cannot guarantee the quick onset nor the precise dosage needed by those who live with diseases like COPD. According to LDS, CannaStrips can guarantee this.
LDS’ CannaStrips are available at All About Wellness in midtown Sacramento.
After a cursory glance at YouTube comment sections and cannabis forums, what immediately springs up is the popularity of CannaStrips.
More importantly, the market seems to appreciate the release of LDS’ product as well. LDS is currently up 14.3 percent to $.40.
Hexa Research projects the cannabis-infused edibles market to grow at a CAGR of 17.8 percent from 2018 to 2024 in the US alone.
To quote Equity Guru’s Lukas Kane, “If you’d purchased LDS stock 5 years ago, you’d be up 1,200%. If you bought LDS stock early in 2018 – you’ve taken a hit.”
Delays in product roll-outs have caused some alarm with investors because, naturally, investors want revenue and product deployment.
On November 7, 2018 LDS announced October, 2018 revenues of $1,171,389, through the Rêveur Corporation (formerly knows as CSPA Group).
Now the company has revenue and successfully put its CannaStrips on store shelves in California.
We think 2019 could be LDS’ year.
Full disclosure: Lifestyle Delivery Systems is an Equity Guru marketing client.Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
Latest posts by Ethan Reyes (see all)
- ‘Crazy’ Joe Biden may be standing in the way of the eventual U.S. cannabis explosion - November 21, 2019
- SOL Global (SOL.C) files early warning report for acquisition of Torque (GAME.V) shares - November 13, 2019
- Cresco Labs (CL.C) reprices Origin House (OH.C) acquisition terms to match declining market - November 13, 2019